On September 3, Ilsira®, our original drug for the treatment of severe complications in COVID-19 patients was included in the guidelines of the Ministry of Health of the Russian Federation. This will help ensure the massive use of drug therapy across Russian regions.
Ilsira®(INN: levilimab) is a monoclonal antibody that blocks the interleukin-6 receptor (IL-6R), which plays a key role in the pathological process of COVID-19. The drug is used to prevent cytokine storm, one of the most severe complications of coronavirus infection.
“It is expected that the use of levilimab at the very onset of clinical manifestations of respiratory failure will allow to avoid the need to bring patients to the intensive care unit. The therapeutic effect of injection occurs within the next 24 hours, reaching its peak, on average, in 96 hours. The inclusion of our drug in the guidelines of the Russian Ministry of Health will enable the large-scale assistance to most vulnerable groups of patients,” said Dmitry Morozov, CEO of BIOCAD. In case of hospitalization, the patients receive drug therapy with levilimab free of charge under the Compulsory Medical Insurance Program.